INIS
administration
17%
aggregation
21%
antibodies
47%
anticoagulants
40%
applications
15%
arachidonic acid
19%
assessments
20%
carbonic anhydrase
12%
comparative evaluations
55%
concentration
38%
coronaviruses
14%
covid-19
28%
data
31%
design
18%
detection
16%
diseases
27%
doses
35%
drugs
44%
evaluation
40%
heparin
18%
humans
28%
in vitro
20%
inflammation
28%
inhibition
26%
kinases
17%
laboratories
27%
levels
23%
management
12%
monitoring
20%
patients
100%
performance
29%
plasma
42%
production
13%
prostaglandins
13%
proteins
28%
rats
13%
receptors
54%
recommendations
12%
reviews
35%
risks
47%
sensitivity
29%
synthesis
23%
thrombin
29%
thrombosis
19%
tissues
13%
tyrosine
17%
urea
15%
vaccines
19%
validation
13%
values
14%
Pharmacology, Toxicology and Pharmaceutical Science
Activated Protein C Resistance
6%
Anticoagulant Agent
16%
Antivitamin K
7%
Apixaban
5%
Arachidonic Acid
10%
Atrial Fibrillation
8%
Bleeding
5%
Blood Stasis
7%
Carbonate Dehydratase
6%
Chronic Myeloid Leukemia
6%
Clinical Study
6%
COVID-19 Vaccine
5%
COX-2 Inhibitor
5%
Dabigatran
14%
Dabigatran Etexilate
9%
Direct Oral Anticoagulant
12%
Heparin
9%
Inflammation
7%
Nanomaterial
9%
Neutralizing Antibody
6%
Oral Contraceptive Agent
5%
Procoagulant
8%
Protein Tyrosine Kinase Inhibitor
6%
Prothrombin
5%
Rivaroxaban
9%
SARS Coronavirus
6%
Thrombin
13%
Thromboembolism
7%
Thromboplastin
5%
Thromboxane
9%
Thromboxane A2
7%
Thromboxane A2 Receptor Blocking Agent
11%
Thromboxane Receptor
13%
Thromboxane Receptor Blocking Agent
8%
Thromboxane Synthase
5%
Thromboxane Synthase Inhibitor
13%
Vaccination Policy
6%
Venous Thromboembolism
5%